IPO Price Range: ₹56 - 58
Min Investment
₹1,16,000
IPO Size
₹29 Cr
IPO Status
Quantity in 1 Lot
2000
Max Bid allowed
1
Listing Exchange
NSE
Bid Opening Date | 25 Jul 2024 |
Bid Closing Date | 29 Jul 2024 |
Allotment Date | 30 Jul 2024 |
Issue Size | ₹29.23Cr |
Quantity in 1 lot | 2000 |
Rapid growth in the business with focus on setting up of healthcare infrastructure.
Track record of execution capabilities of setting up ICUs NICUs PICUs as well as Operation Theatre.
Firm arrangement with many medical equipment suppliers and manufacturers.
Wide customer base including many Private and Government Hospital /Medical college.
Experienced Promoters with technical team having domain knowledge.
Asset light scalable business model.
Loss of any of its key customers or significant reduction in demand from, its significant customers may materially and adversely affect its business and financial performance.
Many of its work orders are awarded primarily through competitive bidding processes. There is no assurance that future contracts will be awarded to it by these customers. Also, the tenders floated by the government agencies have terms that aresuitable to such agencies. This may result in an adverse effect on its business growth, financial and results of operations.
The company depends significantly on customers and their spending in the healthcare infrastructure industry and any decline in the spending on healthcare infrastructure in India, could adversely affect its business and profitability.
Its Order Book may not be representative of its future results and its actual income may be significantly less than the estimates reflected in its Order Book, which could adversely affect its results of operations.
The company has diversified into the business related to installation, set up & maintenance of ICU, NICU, PICU and Operation Theatre in the recent past and are subject to risks associated with new offerings and may not successfully implement its new business models.
The company faces risks relating to sourcing medical equipments from third parties. Failure of such third parties to meet their obligationscould adversely affect its business and results of operations.
Any delays in the completion of its current and future projects could lead to termination of work orders or cost overruns, which could have an adverse effect on its cash flows, business, results of operations and financial condition.
Certain of its properties, including the Registered Office, Branch Office and Warehouse are leased from its promoters, directors and third parties. There can be no assurance that these lease agreements will be renewed upon termination or that its will be able to obtain other premises on lease on same or similar commercial terms.
The company is required to obtain, renew or maintain certain statutory and regulatory permits and approvals required to operate its business and if its fail to do so in a timely manner or at all and its business, financial conditions, results of operations, and cash flows may be adversely affected.
The company derives a significant portion of its revenue from the state of Rajasthan and any adverse developments in these market could adversely affect its business.
Investors | Holdings % |
Saurabh Kishorebhai Bhatt | 49.29% |
Chetan Mohan Joshi | 49.29% |
Archana Chetan Joshi | 0.43% |
Pooja Saurabh Bhatt | 0.43% |
Organisation | Aprameya Engineering Ltd |
Headquarters | Ahmedabad |
Industry | Healthcare |